Herceptin Market Report 2026

Herceptin Market Overview

• Herceptin market size has reached to $7.48 billion in 2025 • Expected to grow to $9.92 billion in 2030 at a compound annual growth rate (CAGR) of 5.8% • Growth Driver: Increasing Incidence Of Breast Cancer Fueling The Growth Of The Market Due To Rising Patient Cases And Demand For Targeted Therapies • Market Trend: Advanced Technologies In Innovative Biosimilar Products Fuels The Market Growth Due To Cost-Effective Treatment And Increasing Patient Access • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Herceptin Market?

Herceptin, also known as trastuzumab, is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2/neu receptor, which promotes the growth of cancer cells. By binding to this receptor, herceptin inhibits tumor cell proliferation and flags them for destruction by the immune system. The main products of herceptin are biologic and biosimilar. Biologics are complex, large-molecule drugs derived from living organisms, used to treat various diseases, including cancer. The various payers include commercial, private, and public, used in different applications, including breast cancer and gastric cancer, and treatment is distributed through several distribution channels, such as hospital pharmacies and specialty pharmacies.

What Is The Herceptin Market Growth Forecast?

The herceptin market size is expected to see strong growth in the next few years. It will grow to $9.92 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing biosimilar competition, rising demand for affordable biologic therapies, expansion of targeted oncology pipelines, growing adoption of personalized cancer treatment, increasing investment in biologic drug innovation. Major trends in the forecast period include increasing adoption of biosimilar trastuzumab products, growing use of subcutaneous formulations, expansion of combination therapy regimens, rising focus on cost-effective biologic treatments, enhanced monitoring of treatment outcomes.

Global Herceptin Market Segmentation

1) By Product: Biologic, Biosimilar 2) By Application: Breast Cancer, Gastric Cancer 3) By Payer: Commercial And Private, Public 4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy Subsegments: 1) By Biologic: Intravenous (IV) Biologics, Subcutaneous (SC) Biologic 2) By Biosimilar: Intravenous (IV) Biosimilars, Subcutaneous (SC) Biosimilars

What Is The Driver Of The Herceptin Market?

The increasing incidence of breast cancer is expected to propel the growth of the herceptin market going forward. Breast cancer is a type of cancer that forms in the cells of the breast, usually starting in the milk ducts or lobules. It includes invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The rise in breast cancer is partly due to lifestyle changes, such as increased alcohol consumption, poor diet, and lack of physical activity, which contribute to a higher risk. As more people are diagnosed with breast cancer, particularly HER2-positive cases, the demand for effective targeted therapies such as herceptin continues to rise. For instance, in January 2025, according to the American Cancer Society, a US-based cancer organization, an estimated 319,750 new cases of breast cancer are expected to be reported in 2025, with approximately 42,680 deaths projected from the disease. Thus, the increasing incidence of breast cancer is driving the expansion of the herceptin industry.

Key Players In The Global Herceptin Market

Major companies operating in the herceptin market are Roche Holding AG, Pfizer Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Biocon Limited, Dr. Reddy’s Laboratories, Celltrion Inc., Samsung Biologics, Fresenius Kabi, Intas Pharmaceuticals Ltd, Zydus Lifesciences Ltd, AryoGen Pharmed, Shanghai Henlius Biotech Inc., Prestige Biopharma Pte Ltd, Alvotech, Coherus BioSciences, BioXpress Therapeutics, Amneal Pharmaceuticals, Novartis AG

Global Herceptin Market Trends and Insights

Major companies operating in the herceptin market are developing novel treatment options, such as innovative biosimilar products, to enhance patient access and improve therapeutic outcomes for HER2-positive cancers. Innovative biosimilar products are highly similar versions of approved biologic drugs that are developed using advanced biotechnology to ensure comparable safety, efficacy, and quality. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to herceptin (trastuzumab), for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars such as HERCESSI demonstrate comparable efficacy and safety to their reference biologics while potentially offering more cost-effective treatment options.

What Are Latest Mergers And Acquisitions In The Herceptin Market?

In October 2025, Teva Pharmaceutical Industries Ltd., an Israel-based global pharmaceutical company, entered a license agreement with Prestige Biopharma, to commercialize Tuznue in Europe. The agreement aims to expand Tuznue’s market presence, enhance patient access to innovative therapies, and strengthen both companies’ positions in the European biopharmaceutical market. Prestige Biopharma is a US-based biopharmaceutical company specializes in the development and commercialization of biologic therapies.

Regional Outlook

North America was the largest region in the herceptin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Herceptin Market?

The herceptin market consists of sales of trastuzumab, trastuzumab deruxtecan, and ado-trastuzumab emtansine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Herceptin Market Report 2026?

The herceptin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the herceptin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.